Cargando…

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments

SIMPLE SUMMARY: Since the advent of trastuzumab in HER2-positive metastatic breast cancer management, the natural history of this disease continues to improve. The development of molecular biology and better knowledge of the resistance mechanisms of cancer cells have enabled the development of sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Essadi, Ismail, Benbrahim, Zineb, Kaakoua, Mohamed, Reverdy, Thibaut, Corbaux, Pauline, Freyer, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046228/ https://www.ncbi.nlm.nih.gov/pubmed/36980624 http://dx.doi.org/10.3390/cancers15061738

Ejemplares similares

Methods and Designs of Modern Breast Cancer Confirmatory Trials
por: Péron, Julien, et al.
Publicado: (2021)

Eighteen Years of Medical Oncology in Morocco: A Bibliometric Evaluation
por: Kaakoua, Mohamed, et al.
Publicado: (2023)

Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
por: Reverdy, Thibaut, et al.
Publicado: (2020)

Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives
por: Varnier, Romain, et al.
Publicado: (2021)

Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study
por: Maugeais, Madeleine, et al.
Publicado: (2022)

Unusual penile localization of melanoma
por: Kaakoua, Mohamed, et al.
Publicado: (2022)

Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer
por: Porter, Karlyn, et al.
Publicado: (2017)

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
por: Hamizi, Salima, et al.
Publicado: (2013)

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
por: Vega Cano, Kreina Sharela, et al.
Publicado: (2022)

Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes
por: de la Bruyère, Charline Lafayolle, et al.
Publicado: (2021)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
por: Lebert, Julie, et al.
Publicado: (2022)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Current approaches to the management of Her2-negative metastatic breast cancer
por: Gogineni, Keerthi, et al.
Publicado: (2012)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

ASCO 2018: highlights in HER2-positive metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2018)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
por: Beasley, Marcie, et al.
Publicado: (2023)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Metastatic collecting duct carcinoma of the kidney treated with sunitinib
por: Tazi, El Mehdi, et al.
Publicado: (2011)

Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer)
por: Falcon, Silvia, et al.
Publicado: (2022)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

The antitumor immune response in HER-2 positive, metastatic breast cancer patients
por: Juranic, Zorica D, et al.
Publicado: (2005)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
por: Jeyakumar, Alwin, et al.
Publicado: (2012)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021)

How we treat patients with metastatic HER2-positive breast cancer
por: Nader-Marta, G., et al.
Publicado: (2022)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
por: Sanglier, Thibaut, et al.
Publicado: (2022)

Retraction: metastatic collecting duct carcinoma of the kidney treated with Sunitinib
por: Tazi, El Mehdi, et al.
Publicado: (2011)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

Current neoadjuvant treatment options for HER2-positive breast cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2021)

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
por: Bartsch, Rupert
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ht4s3apcstlmofshoc8fapcv67